Goldman Sachs’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,021,177
| Closed | -$19M | – | 5862 |
|
|
2020
Q3 | $19M | Buy |
2,021,177
+356,220
| +21% | +$3.39M | 0.01% | 1771 |
|
|
2020
Q2 | $12.7M | Sell |
1,664,957
-233,474
| -12% | -$1.79M | ﹤0.01% | 2077 |
|
|
2020
Q1 | $11.7M | Sell |
1,898,431
-189,659
| -9% | -$1.67M | ﹤0.01% | 1956 |
|
|
2019
Q4 | $25.4M | Buy |
2,088,090
+1,090,709
| +109% | +$11.9M | 0.01% | 1662 |
|
|
2019
Q3 | $11.5M | Buy |
997,381
+885,345
| +790% | +$9.32M | ﹤0.01% | 2216 |
|
|
2019
Q2 | $1.12M | Sell |
112,036
-80,615
| -42% | -$870K | ﹤0.01% | 3924 |
|
|
2019
Q1 | $2.48M | Sell |
192,651
-38,573
| -17% | -$574K | ﹤0.01% | 3478 |
|
|
2018
Q4 | $3.51M | Buy |
231,224
+48,526
| +27% | +$925K | ﹤0.01% | 3163 |
|
|
2018
Q3 | $3.65M | Buy |
182,698
+30,971
| +20% | +$705K | ﹤0.01% | 3201 |
|
|
2018
Q2 | $2.96M | Sell |
151,727
-17,300
| -10% | -$383K | ﹤0.01% | 3330 |
|
|
2018
Q1 | $3.41M | Sell |
169,027
-62,628
| -27% | -$1.06M | ﹤0.01% | 3201 |
|
|
2017
Q4 | $3.07M | Sell |
231,655
-399,816
| -63% | -$6.03M | ﹤0.01% | 3421 |
|
|
2017
Q3 | $11.7M | Buy |
631,471
+71,881
| +13% | +$1.34M | ﹤0.01% | 2446 |
|
|
2017
Q2 | $10.3M | Sell |
559,590
-48,390
| -8% | -$959K | ﹤0.01% | 2496 |
|
|
2017
Q1 | $13.7M | Buy |
607,980
+376,139
| +162% | +$9.01M | ﹤0.01% | 2175 |
|
|
2016
Q4 | $8.07M | Buy |
231,841
+166,728
| +256% | +$4.98M | ﹤0.01% | 2631 |
|
|
2016
Q3 | $1.6M | Sell |
65,113
-20,750
| -24% | -$519K | ﹤0.01% | 4009 |
|
|
2016
Q2 | $2.05M | Sell |
85,863
-192,188
| -69% | -$4.41M | ﹤0.01% | 3601 |
|
|
2016
Q1 | $6.51M | Buy |
278,051
+102,061
| +58% | +$2.42M | ﹤0.01% | 2542 |
|
|
2015
Q4 | $5.31M | Buy |
175,990
+34,610
| +24% | +$1.12M | ﹤0.01% | 2763 |
|
|
2015
Q3 | $5.62M | Sell |
141,380
-40,472
| -22% | -$2.51M | ﹤0.01% | 2786 |
|
|
2015
Q2 | $12.6M | Buy |
181,852
+114,248
| +169% | +$7.19M | ﹤0.01% | 2156 |
|
|
2015
Q1 | $3.69M | Buy |
67,604
+3,998
| +6% | +$191K | ﹤0.01% | 3187 |
|
|
2014
Q4 | $2.71M | Sell |
63,606
-32,117
| -34% | -$1.16M | ﹤0.01% | 3542 |
|
|
2014
Q3 | $3.06M | Buy |
95,723
+35,448
| +59% | +$756K | ﹤0.01% | 3510 |
|
|
2014
Q2 | $1.25M | Sell |
60,275
-138,650
| -70% | -$2.56M | ﹤0.01% | 4484 |
|
|
2014
Q1 | $3.85M | Buy |
198,925
+66,594
| +50% | +$1.41M | ﹤0.01% | 3322 |
|
|
2013
Q4 | $3.21M | Buy |
132,331
+54,180
| +69% | +$1.27M | ﹤0.01% | 3566 |
|
|
2013
Q3 | $1.68M | Buy |
78,151
+13,859
| +22% | +$327K | ﹤0.01% | 4093 |
|
|
2013
Q2 | $1.43M | Buy |
+64,292
| New | +$1.42M | ﹤0.01% | 4055 |
|
Goldman Sachs's AMAG Position: Q4 2020 in Review
Goldman Sachs sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 2,021,177 shares — an estimated $19M sold.
Goldman Sachs first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $25.4M in Q4 2019. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Goldman Sachs reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Goldman Sachs sold 2,021,177 AMAG Pharmaceuticals shares in Q4 2020, an estimated $19M.
- Goldman Sachs first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Goldman Sachs's AMAG Pharmaceuticals position peaked at $25.4M in Q4 2019.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.